Abbott Labs Sells Branded Generics Business to Mylan for 110M Shares

Abbott Laboratories completed the sale of its developed markets branded generics pharmaceuticals business to Mylan in exchange for 110 million ordinary shares of Mylan N.V. on February 27, 2015. An unaudited pro forma consolidated balance sheet of Abbott as of December 31, 2014 assumes the sale occurred on that date. The statement is intended for informational purposes only and does not represent Abbott's actual financial position or future financial performance.